S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
NASDAQ:KRTX

Karuna Therapeutics Stock Forecast, Price & News

$107.84
+5.64 (+5.52%)
(As of 01/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$100.95
$107.90
50-Day Range
$102.20
$134.65
52-Week Range
$94.90
$161.98
Volume
189,749 shs
Average Volume
214,424 shs
Market Capitalization
$3.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.75
30 days | 90 days | 365 days | Advanced Chart
Receive KRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Karuna Therapeutics logo

About Karuna Therapeutics

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRTX
Fax
N/A
Employees
63
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$12.64 per share

Profitability

Net Income
$-68.55 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
24,262,000
Market Cap
$3.19 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/28/2022
Next Earnings (Estimated)
2/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

227th out of 1,417 stocks

Pharmaceutical Preparations Industry

97th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Karuna Therapeutics (NASDAQ:KRTX) Frequently Asked Questions

Is Karuna Therapeutics a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Karuna Therapeutics stock.
View analyst ratings for Karuna Therapeutics
or view top-rated stocks.

How has Karuna Therapeutics' stock price been impacted by COVID-19?

Karuna Therapeutics' stock was trading at $78.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KRTX shares have increased by 36.9% and is now trading at $107.84.
View which stocks have been most impacted by COVID-19
.

When is Karuna Therapeutics' next earnings date?

Karuna Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Karuna Therapeutics
.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) announced its earnings results on Thursday, November, 4th. The company reported ($1.72) EPS for the quarter, missing analysts' consensus estimates of ($1.47) by $0.25.
View Karuna Therapeutics' earnings history
.

What price target have analysts set for KRTX?

13 analysts have issued 1 year price targets for Karuna Therapeutics' shares. Their forecasts range from $150.00 to $185.00. On average, they anticipate Karuna Therapeutics' share price to reach $167.58 in the next year. This suggests a possible upside of 55.4% from the stock's current price.
View analysts' price targets for Karuna Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Karuna Therapeutics' key executives?

Karuna Therapeutics' management team includes the following people:
  • Steven Marc Paul, Chairman, President & Chief Executive Officer
  • Andrew Miller, Chief Operating Officer
  • Troy A. Ignelzi, Chief Financial Officer & Secretary (LinkedIn Profile)
  • Stephen Brannan, Chief Medical Officer
  • Ronald Marcus, Senior Vice President-Medical

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an IPO on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Karuna Therapeutics' stock symbol?

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Catalyst Private Wealth LLC (0.08%), Allspring Global Investments Holdings LLC (0.02%), Russell Investments Group Ltd. (0.02%), Exane Derivatives (0.00%) and Lindbrook Capital LLC (0.00%). Company insiders that own Karuna Therapeutics stock include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends for Karuna Therapeutics
.

Which major investors are buying Karuna Therapeutics stock?

KRTX stock was acquired by a variety of institutional investors in the last quarter, including Catalyst Private Wealth LLC, Allspring Global Investments Holdings LLC, Russell Investments Group Ltd., Exane Derivatives, and Lindbrook Capital LLC. Company insiders that have bought Karuna Therapeutics stock in the last two years include Heather Preston, James Healy, and Steven M Paul.
View insider buying and selling activity for Karuna Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karuna Therapeutics' stock price today?

One share of KRTX stock can currently be purchased for approximately $107.84.

How much money does Karuna Therapeutics make?

Karuna Therapeutics has a market capitalization of $3.19 billion. The company earns $-68.55 million in net income (profit) each year or ($4.88) on an earnings per share basis.

How many employees does Karuna Therapeutics have?

Karuna Therapeutics employs 63 workers across the globe.

What is Karuna Therapeutics' official website?

The official website for Karuna Therapeutics is karunatx.com.

Where are Karuna Therapeutics' headquarters?

Karuna Therapeutics is headquartered at 33 ARCH STREET SUITE 3110, BOSTON MA, 02110.

How can I contact Karuna Therapeutics?

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The company can be reached via phone at (857) 449-2244 or via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]tbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.